Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpower133: Atezolizumab in ES-SCLC
NCT02763579Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
A Phase 3 trial of atezolizumab in small cell lung cancer (SCLC), sponsored by Roche. Started Jun 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02763579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763579.